Mouse uterine tumors were examined for genetic alterations in the ras proto-oncogene and p53 tumor suppressor gene arid for other biologically relevant immunohistochemical markers that may increase our understanding of the events that occur in uterine cancer. Fourteen dimethylhydrazine (DMH)-induced uterine sarcomas, including 3 primary malignant fibrous histiocytomas (MFH), 7 transplanted MFH, 3 stromal sarcomas, and 1 undifferentiated sarcoma, were first screened by immunohistochemistry for p53 missense mutations, followed by single strand conformation polymorphism analysis and DNA sequencing for the identification of point mutations. There was 100% correlation between p53 protein immunopositivity and subsequent detection ofp53 mutations in DMH-induced malignant fibrous histiocytomas. All MFH had a characteristic p53 G:C→A:T transition mutation, consistent with O6-methylguanine mispairing with thymine, the most common DNA lesion caused by alkylating agents. DMH-induced uterine MFH with p53 mutations also had a higher proliferative rate (qualitatively evaluated by immunohistochemical detection of proliferating cell nuclear antigen) when compared with other DMH-induced sarcomas. Uterine sarcomas were further evaluated for biological end points, such as estrogen receptor and desmin. Neoplastic cells from stromal sarcomas (SS), undifferentiated sarcomas (US), and MFH did not stain for desmin. The estrogen receptor was detected in normal uteri and a small portion of MFH, SS, and US. Our data suggest that DMH-induced uterine sarcomas are not consistent with smooth muscle cell origin and that a subset of these tumors, specifically DMH-induced malignant fibrous histiocytomas, have unique p53 G:C→A:T transitions and a high proliferative rate.
1. Anderson MW, Reynolds SH, You M, and Maronpot RM (1992). Role of proto-oncogene activation in carcinogenesis. Environ. Health Perspect.98: 13–24.
2.
2. Andreassen A, Oyjord T, Hovig E, Holm R, Florenes VA, Nesland JM, Myklebost O, Hoie J, Bruland OS, Borresen AL, and Fodstad 0 (1993). p53 abnormalities in different subtypes of human sar comas. Cancer Res.53: 468–471.
3.
3. Barbacid M (1987). ras Genes. Annu. Rev. Biochem.56: 780–813.
4.
4. Bartsch H, Terracini B, Malaveille C, Tomatis L, Wahrendorf J, Brun G, and Dodet B (1983). Quantitative comparison of carcinogenicity, mutagenicity and electrophilicity of 10 direct-acting alkylating agents and of the initial O6:7-alkylguanine ratio in DNA with carcinogenic potency in rodents. Mutat. Res.110: 181–219.
5.
5. Basu AK and Essigmann JM (1988). Site-specifically modified oli-godeoxynucleotides as probes for the structural and biological effects of DNA-damaging agents. Chem. Res. Toxicol.1: 1–18.
6.
6. Boyd J and Risinger JI (1991). Analysis of oncogene alterations in human endometrial carcinoma: Prevalence of ras mutations. Mol. Carcinog.4: 189–195.
7.
7. Burns PA, Gordon AJE, Kunzman K, and Glickman B (1988). Influence of neighbouring base sequence on the distribution and repair of ENU-induced lesions in Escherichia coli. Cancer Res.48: 4455–4458.
8.
8. Cattoretti G, Rilke F, Andreola S, D'Amato L. and Delia E (1988). p53 expression in breast cancer. Int. J. Cancer41: 178–183.
9.
9. Chouroulinkow I, Guillon JC, and Guerin M (1969). Endometrial sarcomas in mice: A survey of 130 cases. J. Natl. Cancer Inst.42: 593–603.
10.
10. Devereux TR, Anderson MW, and Belinsky SA (1991). Role of ras protooncogene activation in the formation of spontaneous and ni-trosamine-induced lung tumors in the resistant C3H mouse. Carcinogenesis12: 299–303.
11.
11. Duggan BD, Felix JC, Muderspach LI, Tsao J, and Shibata DK (1994). Early mutational activation of the c-Ki-ras oncogene in endometrial carcinoma. Cancer Res.54: 1604–1607.
12.
12. Frei JV, Swenson DH, Warren W, and Lawley PD (1978). Alkylation of deoxyribonucleic acid in vivo in various organs of C57B1 mice by the carcinogens N-methyl-N-nitrosourea, N-ethyl-N-nitro-sourea and ethyl methanesulphonate in relation to induction of thymic lymphoma. Biochem. J.174: 1031–1044.
13.
13. Goodrow TL, Storer RD, Leaner KR, Prahalada SR, van Zwieten MJ, and Bradley MO (1992). Murine p53 intron sequences 5-8 and their use in polymerase chain reaction/direct sequencing analysis of p53 mutations in CD-I mouse liver and lung tumors. Mol. Carcinog.5: 9–15.
14.
14. Greenblatt MS, Bennett WP, Hollstein M, and Harris CC (1994). Mutations in the p53 tumor suppressor gene: Clues to cancer etiology and molecular pathogenesis. Cancer Res.54: 4855–4878.
15.
15. Greenwell A, Foley JF, and Maronpot RR (1991). An enhancement method for immunohistochemical staining of proliferating cell nuclear antigen in archival rodent tissues. Cancer Lett.59: 251–256.
16.
16. Haapasalo H, Isola J, Sallinen P, Kalimo H, Helin H, and Rantala1 (1993). Aberrant p53 expression in astrocytic neoplasms of the brain: Association with proliferation. Am. J. Pathol.142: 1347–1351.
17.
17. Harris CC (1996). Structure and function of the p53 tumor suppressor gene: Clues for rational cancer therapeutic stratagies. J. Natl. Cancer Inst.88: 1442–1455.
18.
18. Hegi ME, Soderkvist P, Foley JF, Schoonhoven R, Swenberg JA, Kari F, Maronpot R, Anderson MW, and Wiseman RW, (1993). Characterization of p53 mutations in methylene chloride-induced lung tumors from B6C3F1 mice. Carcinogenesis14: 803–810.
19.
19. Hollstein M, Sidransky D, Vogelstein B, and Harris CC (1991). p53 mutations in human cancers. Science253: 49–53.
20.
20. Hong HL, Devereux TR, Melnick RL, Eldridge SR, Greenwell A, Haseman J, Boorman GA, and Sills RC (1997). Both K-ras and H-ras protooncogene mutations are associated with Harderian gland tumorigenesis in B6C3FI mice exposed to isoprene for 26 weeks. Carcinogenesis18: 783–789.
21.
21. Hongyo T, Buzard GS, Calvert RJ, and Weghorst CM (1993). “Cold SSCP”: A simple, rapid and non-radioactive method for optimized single-strand conformation polymorphism analyses. Nucleic Acids Res.21: 3637–3642.
22.
22. Horsfall MJ, Gordon AJE, Burns PA, Zielenska M, van der Vliet GME and Glickman BW (1990). Mutational specificity of alkylating agents and the influence of DNA repair. Environ. Mol. Mutagen.15: 107–122.
23.
23. Hsu SM, Raine L, and Fanger H (1981). Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: A comparison between ABC and unlabeled antibody (PAP) procedures. J. Histochem. Cytochem.29: 577–580.
24.
24. Ingle CA and Drinkwater NR (1989). Mutational specificities of I-acetoxysafrole, N-benzoyIoxy-N-methyl-4-aminoazobenzene, and ethyl methanesulfonate in human cells. Mutat. Res.220: 133–142.
25.
25. Koutsilieris M (1992). Pathophysiology of uterine leimyomas. Biochem. Cell Biol.70: 273–278.
26.
26. Liu F, Kohler MF, Marks JR, Bast RC, Boyd J, and Berchuck A (1994). Mutation and overexpression of the p53 tumor suppressor gene frequently occurs in uterine and ovarian sarcomas. Obstet. Gynecol.83: 118–124.
27.
27. Meden H, Meyer RD, Schauer A, and Kuhn W (1991). Endometrial stromal sarcomas of the uterus. Anticancer Drugs2: 35–37.
28.
28. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hostetter RH, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P, Glover T, Collins FS, Weston A, Modali R, Harris CC, and Vogelstein B (1989). Mutations in the p53 gene occur in diverse human tumour types. Nature342: 705–708.
29.
29. Rao GN, Collins BJ, Giles HD, Heath JE, Foley JF, May RD, and Buckley LA (1996). Carcinogenicity of 2',3'-dideoxycytidine in mice. Cancer Res.56: 4666–4672.
30.
30. Richardson KK, Richardson FC, Crosby RM, Swenberg JA, and Skopek TR (1987). DNA base changes and alkylation following in vivo exposure of Escherichia coli to N-methyl-N-nitrosourea or N-ethyl-N-nitrosourea. Proc. Natl. Acad. Sci. USA84: 344–348.
31.
31. Ruggeri B, DiRado M, Zhang SY, Bauer B, Goodrow T, and Klein-Szanto AJP (1993). Benzo[a]pyrene-induced murine skin tumors exhibit frequent and characteristic G to T mutations in the p53 gene. Proc. Natl. Acad. Sci. USA90: 1013–1017.
32.
32. Saiki RK, Gelfand DH, Stoffel S, Scharf SJ, Higuchi R, Horn GT, Mullis KB, and Erlich HA (1988). Primer-directed enzymatic amplification of DNA with a thermostable DNA polymerase. Science239: 487–490.
33.
33. Sills RC, Hong HL, Greenwell A, Herbert RA, Boorman GA, and Devereux TR (1995). Increased frequency of K-ras mutations in lung neoplasms from female B6C3F1 mice exposed to ozone for 24 or 30 months. Carcinogenesis16: 1623–1628.
34.
34. Strauss BS (1992). The origin of point mutations in human tumor cells. Cancer Res.52: 249–253.
35.
35. Suurmeijer AJ and Boon ME (1993). Notes on the application of microwave antigen retrieval in paraffin and plastic tissue. Eur. J. Morphol.31: 144–150.
36.
36. Trukhanova LS (1986). Influence of 1,2-dimethylhydrazine on es-trus cycle in mice of different strains. Exp. Oncol.8: 22–23 (in Russian).
37.
37. Turusov VS, Kondalenko VF, and Trukhanova LS (1993). Mouse uterine tumors resembling malignant fibrous histiocytoma: Light and electron microscopic study. Exp. Oncol. (Kiev)15: 41–46.
38.
38. Turusov VS, Morozova OV, and Samollov DV (1994). Estrogen modification of 1,2-dimethylhydrazine carcinogenesis in C3HA mice. Cancer Lett.83: 51–58.
39.
39. Turusov VS, Munoz N, and Dunn TB (1994). Tumours of the vagina and uterus. IARC Sci. Publ.111: 451–491.
40.
40. Turusov VS, Raikhlin NT, Smirnov EA, and Trukhanova LS (1993). Uterine sarcomas induced in mice by combined treatment with 1,2-dimethylhydrazine and estradiodiproprionate. Exp. Toxicol. Pathol.45: 161–166.
41.
41. van Kranen HJ, de Gruijl FR, de Vries A, Sontag Y, Wester PW, Senden CM, Rozemuller E, and van Kreijl CF (1995). Frequent p53 alterations but low incidence of ras mutations in UV-B-induced skin tumors of hairless mice. Carcinogenesis16: 1141–1147.
42.
42. van Kranen HJ, de Laat A, van de Ven J, Wester PW, de Vries A, Berg RJW, van Kreijl CF, and de Gruijl FR (1997). Low incidence of p53 mutations in UVA (365-nm)-induced skin tumors in hairless mice. Cancer Res.57: 1238–1240.
